Elsevier and the Society of Hospital Medicine announce joint initiative aimed at helping patients with underlying substance use disorders

Elsevier, a global leader in evidence-based clinical practice content, research publishing and information analytics, today announced that it will partner with the Society of Hospital Medicine (SHM) in the development of materials to help hospitalists at the point-of-care with the identification, inpatient management, and discharge planning of patients with underlying substance use disorders (SUD). More than 17 million U.S. adults are affected by SUD and its underlying health conditions.

As part of this initiative, Elsevier has provided grant support to enable the Society of Hospital Medicine to develop a suite of tools and resources for hospitalists that will help them in identifying patients with SUD, initiating medications for opioid use disorder (MOUD) in the hospital setting, and supporting patient discharge to the home or community. Faculty working on the project have access to evidence-based information through Elsevier’s ClinicalKey® to inform their research. At project completion, SHM will contribute to the creation of point-of-care recommendations on the topic within ClinicalKey, allowing ClinicalKey users to quickly access the information, while reinforcing best practices recommended by SHM.

“Hospitalization represents an important step in identifying and treating patients with SUD,” said Josh Schoeller, President, Clinical Solutions, Elsevier. “It’s imperative to support hospitalists in acquiring the knowledge, evidence-based strategies and tools to effectively manage this patient population and address the growing health crisis in our country.”

The first output of this project, due to release this year, will be a discussion guide to support hospitalists in conducting patient-centered discussions with individuals who have a diagnosis of SUD with a focus on Opioid Use Disorder (OUD) including best practices and clinical scenarios in a case study format which review how to identify patients with OUD, initiate treatment and facilitate effective transitions of care strategies.

“We’re pleased to collaborate with Elsevier on this important initiative that we believe will have an impact in the health and wellbeing of many Americans suffering from substance use disorders,” said Jenna Goldstein, Director of SHM’s Center for Quality Improvement.

---

Notes for editors

About the Society of Hospital Medicine

Representing the fastest growing specialty in modern healthcare, the Society of Hospital Medicine (SHM) is celebrating 25 years as the leading medical society for hospitalists and their patients. SHM is dedicated to promoting the highest quality care for all hospitalized patients and overall excellence in the practice of hospital medicine through quality improvement, education, advocacy, and research. Over the past decade, studies have shown that hospitalists can contribute to decreased patient lengths of stay, reductions in hospital costs and readmission rates, and increased patient satisfaction. For more information about SHM and hospital medicine, visit hospitalmedicine.org.

About Elsevier

Elsevier is a global leader in advanced information and decision support. For over a century, we have been helping advance science and healthcare to advance human progress. We support academic and corporate research communities, doctors, nurses, future healthcare professionals and educators across 170 countries in their vital work. We do this by delivering mission-critical insights and innovative solutions that combine trusted, evidence-based scientific and medical content with cutting-edge AI technologies to help impact makers achieve better outcomes. We champion inclusion and sustainability by embedding these values into our products and culture, working with the communities that we serve. The Elsevier Foundation supports research and health partnerships around the world.

Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. For more information, visit www.elsevier.com and follow us on social media @ElsevierConnect.